Article
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jan 2016
Wilson Melissa A, Zhao Fengmin, Khare Sanika, Roszik Jason, Woodman Scott E, D'Andrea Kurt, Wubbenhorst Bradley, Rimm David L, Kirkwood John M, Kluger Harriet M, Schuchter Lynn M, Lee Sandra J, Flaherty Keith T, Nathanson Katherine L
Abstract excerpt
PURPOSE: Copy number alterations have been shown to be involved in melanoma pathogenesis. The randomized phase III clinical trial E2603: carboplatin, paclitaxel, ± sorafenib (CP vs. CPS) offers a large collection of tumor samples to evaluate association of somatic mutations, genomic alterations, and clinical outcomes, prior to current FDA-approved therapies. EXPERIMENTAL DESIGN: Copy number and mutational...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.